Jennifer R. Brown, MD, PhD

Jennifer R. Brown, MD, PhD, discusses the design of the AMPLIFY trial and safety data for acalabrutinib plus venetoclax in chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, discusses ongoing clinical trials that she has her eye out for in chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinb and venetoclax for chronic lymphocytic leukemia and its effect on patient QOL.

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Jennifer R. Brown, MD, PhD, Director, CLL Center, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the recent progress seen in the treatment landscape of chronic lymphocytic leukemia (CLL), and what still needs to be accomplished going forward.